RxDoctor Payments Data

Scott Tran, MD

Internal Medicine · Anaheim, CANPI 1922183342

Payments from drug & device makers

$4,854in general payments, 2019–2025

Across 265 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Gilead$1K
  • Bayer$857
  • AstraZeneca$241
  • Johnson & Johnson$235
  • Amarin Pharma, Inc.$151
  • plus $580 from 12 others

What the payments were for

  • Food & beverage$4,833100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,854 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$88,353
Medicare patients
94
Services billed
884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl377$137,509
VemlidyTenofovir Alafenamide88$120,396
ProliaDenosumab66$111,041
JardianceEmpagliflozin107$86,972
TradjentaLinagliptin109$83,151
KerendiaFinerenone95$76,755
Diclofenac Sodium300$76,292
JanuviaSitagliptin Phosphate101$71,678
Dexlansoprazole DrDexlansoprazole189$40,521
Icosapent Ethyl158$36,185
Bydureon BciseExenatide Microspheres24$19,904
LivaloPitavastatin Calcium55$18,176
DexilantDexlansoprazole47$15,762
Praluent PenAlirocumab25$11,840
RestasisCyclosporine11$8,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$96$170,124216 claims
GileadVemlidy$1,043$120,39688 claims
AmgenProlia$1,747$111,04166 claims
BayerKerendia$857$76,75595 claims
MerckJanuvia$19$71,678101 claims
Kowa Pharmaceuticals America, Inc.Livalo$36$18,17655 claims
AstraZenecaFarxiga$241$6,87212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →